Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowCantor Fitzgerald has downgraded Apellis Pharmaceuticals (APLS) following Biogen's recent acquisition. This decision reflects potential market implications for APLS shares amidst Biogen's active strategic moves. The downgrade is a response to shifts in market sentiment influenced by M&A activities. Investors may want to monitor how this impacts APLS's trading volumes and price movements in the near term.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Biogen Inc. (BIIB)
Biogen is a biotech focused on neurological diseases.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BIIB news
BIIB stock page and all news βGet the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
